drug
RAP-219
Phase 2updated 3mo agoby $RAPP Rapport Therapeutics, Inc.
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying RAP-219
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- phase2Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
- phase2Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
- phase2A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
News(1)
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysIn a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.biopharma_dive · 2mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that